Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Mirum Pharmaceuticals
ISIN US6047491013
|WKN A2PM29
Market cap (in EUR)
5.361 m
Country
Verenigde Staten
Sector
Gezondheidszorg
Dividend yield
0,00%
Overview
Description
Mirum Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf. Het bedrijf richt zich op de ontwikkeling en commercialisering van een laat stadium pijplijn van nieuwe therapieën voor slopende leverziekten. De producten omvatten Maralixibat en Volixibat. Het bedrijf werd in mei 2018 opgericht door Niall O'Donnel, Michael Grey en Christopher Peetz en heeft zijn hoofdkantoor in Foster City, CA.
Gezondheidszorg Biofarmaceutica Systeemspecifieke Biofarmaceutica Verenigde Staten
Financials
Key metrics
| Market capitalisation, EUR | 5.361 m |
| EPS, EUR | -12,47 |
| P/B ratio | 23,6 |
| P/E ratio | - |
| Dividend yield | 0,00% |
Winst- en verliesrekening (2025)
| Revenue, EUR | 462 m |
| Net income, EUR | -21 m |
| Profit margin | -4,48% |
In welke ETF zit Mirum Pharmaceuticals?
Er zijn 42 ETF's die Mirum Pharmaceuticals bevatten. Al deze ETF's staan in de tabel hieronder. De ETF met de grootste weging van Mirum Pharmaceuticals is de L&G Pharma Breakthrough UCITS ETF.
Savings plan offers
Hier vind je informatie over de beschikbaarheid van het beleggingsplan voor dit aandeel. Je kunt de tabel gebruiken om beleggingsplanaanbiedingen voor de geselecteerde investeringsbedrag te vergelijken.
Select your savings amount:
| Broker | Rating | Execution fee | Account fee | |
|---|---|---|---|---|
 | 0,00 € | 0,00 € | View offer* | |
 | 0,00 € | 0,00 € | View offer* |
Detailed comparison of all offers
Source: justETF Research; as of 9/2026. The offers are sorted in the following way: 1. Rating 2. Execution fee 3. Number of stock savings plans. The number of stock savings plans is rounded. In addition to the fees charged by online brokers, additional costs may apply. The stated fees are thus exclusive of standard market spreads, commissions, product costs and third-party fees. Please note: No guarantee can be given for the completeness, correctness and accuracy of the content listed. The information on the online brokers' homepages is decisive. Investments in securities involve risks.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.